A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)

2002 ◽  
Vol 38 ◽  
pp. S88 ◽  
Keyword(s):  
Clinical Trial ◽  
Phase I ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Hydroxamic Acid ◽  
Oral Formulation ◽  
Phase I Clinical Trial ◽  
Suberoylanilide Hydroxamic Acid ◽  
Deacetylase Inhibitor

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

2008 ◽  
Vol 81 (3) ◽  
pp. 170-176 ◽  
Author(s):  
Peter Gimsing ◽  
Mads Hansen ◽  
Lene M. Knudsen ◽  
P. Knoblauch ◽  
Ib Jarle Christensen ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase I ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Phase I Clinical Trial ◽  
Deacetylase Inhibitor

scholarly journals Histone Deacetylase Inhibitors: Synthesis of Tetrapeptide Analogue SAHA/TPX

2011 ◽  
Vol 8 (s1) ◽  
pp. S79-S84
Author(s):  
Lynda Ekou ◽  
Tchirioua Ekou ◽  
Isabelle Opalinski ◽  
Jean Pierre Gesson
Keyword(s):  
Clinical Trial ◽  
Cancer Therapy ◽  
Phase I ◽  
Histone Deacetylase ◽  
Hydroxamic Acid ◽  
Histone Deacetylase Inhibitors ◽  
Hdac Inhibitors ◽  
Growth Arrest ◽  
Suberoylanilide Hydroxamic Acid ◽  
Specific Inhibitors

The inhibition of HDAC (histone deacetylase) activity by specific inhibitors induces growth arrest, differentiation and apoptosis of transformed or several cancer cells. Some of these inhibitors are in clinical trial at phase I or phase II. The discovery and development of specific HDAC inhibitors are helpful for cancer therapy. In this paper we describe the synthesis of simple inhibitorBhybrid analogue suberoylanilide hydroxamic acid (SAHA), trapoxinB(TPX B) in as little as five steps. This compound is interesting lead for the design of potent inhibitors of histone deacetylase.

Sign in / Sign up

Export Citation Format

Share Document